神经内分泌肿瘤肽受体放射性核素治疗后肿瘤囊性坏死
本文报道一例49岁男性转移性直肠神经内分泌肿瘤患者,PRRT后临床症状和RECIST提示疾病进展,但Ga-DOTA-(Tyr3)-octreotate PET/CT显示部分闪烁显像反应且F-FDG PET/CT无摄取,符合肿瘤囊性坏死,长期随访证实肿瘤持续对治疗有反应。
要点
- PRRT后RECIST进展不一定代表治疗失败,需结合功能显像综合判断。
- Ga-DOTA-(Tyr3)-octreotate PET/CT显示部分反应而F-FDG PET/CT无摄取,符合肿瘤囊性坏死。
- 长期随访证实肿瘤持续对PRRT有反应。
核心结论
- 综合运用所有反应评估手段对正确判断PRRT获益似乎很重要,并需在开发反应评估工具时纳入。
研究设计与样本
- 病例报告:一例49岁男性转移性直肠神经内分泌肿瘤患者接受PRRT后的反应评估与长期随访。
主要发现
- 该患者PRRT后临床症状和实体瘤疗效评价标准(RECIST)提示疾病进展。
- Ga-DOTA-(Tyr3)-octreotate PET/CT显示部分闪烁显像反应,且F-FDG PET/CT无摄取,符合肿瘤囊性坏死。
- 长期随访证实肿瘤持续对治疗有反应。
关键数值与推荐
- PRRT后RECIST提示进展,而Ga-DOTA-(Tyr3)-octreotate PET/CT显示部分闪烁显像反应且F-FDG PET/CT无摄取。
临床怎么用
- 作者认为综合运用所有反应评估手段似乎对正确判断PRRT获益很重要,并需在开发反应评估工具时纳入。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The response assessment to peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors is complex. We present the case of a 49-year-old man with metastatic rectal neuroendocrine tumor whose clinical symptoms and response evaluation criteria in solid tumors suggested progressive disease following PRRT. However, Ga-DOTA-(Tyr3)-octreotate PET/CT showed a partial scintigraphic response with absence of F-FDG PET/CT uptake consistent with tumor cystic necrosis. Long-term follow-up confirmed ongoing tumor response to treatment. Utilizing all modalities of response assessment seems to be important in correctly judging the benefit from PRRT and will need to be incorporated when developing response assessment tools.
引用
- Ladwa R, Wen Hong H, Wyld D, et al. Tumor Cystic Necrosis Following Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumors. Clin Nucl Med. 2018. PMID: 29356741. doi:10.1097/RLU.0000000000001970
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。